All articles tagged with #wegovy
Novo Nordisk will cut Wegovy by 50% and Ozempic by 35% starting January 2027, setting a $675 per-month price for both drugs and for Rybelsus as well, as it faces competition from Lilly’s Mounjaro/Zepbound and other GLP-1 therapies; the company says the cuts aim to lower out-of-pocket costs for patients with high-deductible plans, and direct-to-patient discounts will remain unchanged.
Novo Nordisk said U.S. list prices for Wegovy, Ozempic, and Rybelsus will be cut by up to 50% to $675 per month starting Jan. 1, 2027, targeting insured patients with high-deductible plans or co-insurance and potentially lowering out-of-pocket costs; Medicare prices will also drop to $274 per month under the Inflation Reduction Act, aiming to boost access and competition in the GLP-1 market.
England’s health strategy will pay GPs £3,000 a year plus about £1,000 for referring patients to weight‑loss programmes to increase NHS prescriptions of the drug Mounjaro; Wegovy remains prescribed only through NHS weight‑loss services. Access to these drugs on the NHS remains tightly restricted (BMI thresholds and health conditions), with rollout described as patchy. Experts say the incentives may help access but won’t widen eligibility, and concerns about workload and realistic patient eligibility persist as the NHS aims to shift toward prevention and reach an expected 220,000 Mounjaro users by 2028.
The FDA says Novo Nordisk’s Wegovy TV ad makes false or misleading claims, overstating benefits and not adequately presenting risks, and it calls for immediate corrective action that could include halting the ads; the move comes as Novo battles Eli Lilly and copycats in the GLP-1 obesity market, with Wegovy gaining adopters since its January launch.
Novo Nordisk filed a lawsuit seeking a permanent ban and damages against Hims & Hers for allegedly selling compounded, patent-infringing versions of Wegovy (semaglutide); Hims paused its obesity-pill copycat after regulatory scrutiny as FDA actions loom, underscoring a broader crackdown on compounded GLP-1 drugs used by as many as 1.5 million Americans amid intense obesity-drug competition.
Hims & Hers has canceled its plan to develop a Wegovy‑style weight‑loss medication, shelving a project to mimic Novo Nordisk’s semaglutide as the company reassesses its drug‑development strategy in the competitive obesity market.
Hims & Hers will stop selling a cheaper, compounded version of Novo Nordisk’s obesity pill Wegovy after health officials called for an investigation into possible federal-law violations; the platform had offered a $49/month compounded version, while Novo Nordisk’s Wegovy costs $149–$299/month, as FDA and HHS/DOJ actions move to curb unapproved compounded GLP-1 drugs.
Britain's MHRA has warned that the diabetes/weight‑loss injections Ozempic (semaglutide) and Wegovy may cause a rare optic nerve condition (NAION) that can lead to sudden vision loss in one eye. The regulator has received three reports, but says the overall risk is very small; with about two million UK users, patients and clinicians are advised to be alert to symptoms and seek urgent eye care if vision changes occur. The warning also notes that pancreatitis is a known but infrequent side effect of GLP-1 weight‑loss drugs.
Novo Nordisk said it will take legal and regulatory action against telehealth provider Hims & Hers after it unveiled a cheaper copycat Wegovy. Hims plans an oral semaglutide pill priced at $49 for the first month and $99 thereafter under a 5-month plan, triggering about 7% declines in Novo Nordisk and Eli Lilly shares; Novo argues the product is illegal mass compounding that risks patient safety, while Hims says its copy uses a different formulation. Wegovy’s SNAC absorption technology is a key point of contrast, and Lilly is preparing its own oral GLP-1, orforglipron, pending FDA approval.
Novo Nordisk says Hims & Hers’ new $49/month, compounded semaglutide version of Wegovy is illegal mass compounding and unsafe, pledging legal action; the FDA has warned against copycat GLP‑1 drugs. The move intensifies price competition in obesity drugs, with Novo forecasting up to a 13% drop in net sales and shares for Novo Nordisk and Lilly slipping.
Novo Nordisk warned that 2026 sales could fall as much as 13% due to fierce competition from Eli Lilly’s weight-loss drugs and government pricing pressure, marking the first annual decline since Ozempic’s launch; Lilly projected continued growth. The company also reported strong early uptake for a pill version of Wegovy and is pursuing a higher 7.2 mg dose, even as leadership shakeups and patent expirations keep the turnaround challenging and sent Novo's shares lower.
Novo Nordisk warned profits and sales could fall as much as 13% due to unprecedented price pressure on GLP-1 weight‑loss drugs, amplified by a U.S. government price deal. The news sparked an about 18% drop in the stock as the company grapples with competition from Eli Lilly, patent expiries, and ongoing cost-cutting, with CEO Maziar Doustdar saying the cuts are painful but intended to broaden access and drive future growth.
Novo Nordisk warned that 2026 sales and operating profit could fall 5%-13%, pressured by U.S. price competition, a Most Favored Nation pricing deal, currency headwinds, and looming patent expirations abroad; Wegovy momentum supported 2025 results, and the company plans reinvestment from savings amid ongoing layoffs. It also announced leadership changes: Dave Moore is leaving and will be replaced by Jamey Millar, while Ludovic Helfgott is departing with Hong Chow slated to join. Shares fell about 14% after the update.
Novo Nordisk beat 2025 sales estimates but warned that 2026 sales will fall 5%–13% at constant exchange rates, reversing last year’s growth. The drop is driven by expected weaker U.S. sales amid competition from Lilly’s tirzepatide and pricing pressures under MFN reforms, even as international sales may rise with Wegovy expanding into more markets. The outlook sent the stock lower, with U.S.-listed shares sliding about 14% after the report.
Novo Nordisk warned that 2026 sales and operating profit could fall 5%–13% at constant exchange rates due to U.S. pricing pressure and loss of exclusivity for Wegovy and Ozempic in markets like Canada, Brazil and China, sending its shares down as much as 14% after a trading halt. The company cited continued price pressure and intensified competition from Lilly’s weight‑loss drugs, even as it rolled out an oral Wegovy in the U.S. and pursued next‑generation GLP‑1 products. In Q4, net sales were 79.1 billion Danish kroner with Ozempic at 31.8 billion and Wegovy at 21.9 billion, while 2025 saw sales up 10% and operating profit up 6%. Investors are watching for potential U.S. volume gains and how pricing deals and competition will affect 2026 guidance.